Product correctly added to cart.

discount label
Lixisenatide acetate
View 3D

Biosynth logo

Lixisenatide acetate

CAS: 1997361-87-1

Ref. 3D-FL76758

5mg
136.00 €
10mg
194.00 €
25mg
348.00 €
50mg
518.00 €
100mg
863.00 €
Estimated delivery in United States, on Monday 16 Dec 2024

Product Information

Name:
Lixisenatide acetate
Description:

Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that is used to treat type 2 diabetes. Lixisenatide has been shown to be safe and effective in patients with renal impairment, hepatic impairment, or congestive heart failure. The pharmacokinetics of lixisenatide have been studied in healthy subjects and patients with chronic renal failure receiving dialysis. Lixisenatide has been shown to have a linear pharmacokinetic profile in both populations and has not been found to accumulate in the plasma after repeated doses. Lixisenatide does not bind tightly to human serum albumin, which may make it more suitable for use in patients with atherosclerotic cardiovascular disease who exhibit hyperlipidemia because it will be less likely to affect lipid profiles.

Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Biosynth
Long term storage:
Notes:

Chemical properties

Formula:
C215H347N61O65S•(C2H4O2)x
Purity:
Min. 95%
Color/Form:
Powder
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:

Hazard Info

UN Number:
EQ:
Class:
H Statements:
P Statements:
Forbidden to fly:
Hazard Info:
Packing Group:
LQ:

Technical inquiry about: 3D-FL76758 Lixisenatide acetate

Please use instead the cart to request a quotation or an order

If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.

* Mandatory fields.
Welcome to CymitQuimica!We use cookies to enhance your visit. We do not include advertising.

Please see our Cookies Policy for more details or adjust your preferences in "Settings".